Adverse experiences that have been reported with telmisartan, without regard to causality, are listed as follows: Autonomic Nervous System:
impotence, increased sweating, flushing.
Body as a Whole:
allergy, fever, leg pain, malaise, chest pain.
palpitation, dependent edema, angina pectoris, leg edema, abnormal ECG, hypertension, peripheral edema.
insomnia, somnolence, migraine, vertigo, paresthesia, involuntary muscle contractions, hypoaesthesia.
flatulence, constipation, gastritis, dry mouth, hemorrhoids, gastroenteritis, enteritis, gastroesophageal reflux, toothache, non-specific gastrointestinal disorders.
gout, hypercholesterolemia, diabetes mellitus.
arthritis, arthralgia, leg cramps, myalgia.
anxiety, depression, nervousness.
infection, fungal infection, abscess, otitis media.
asthma, rhinitis, dyspnea, epistaxis.
dermatitis, eczema, pruritus.
micturition frequency, cystitis.
abnormal-vision, conjunctivitis, tinnitus, earache.
A single case of angioedema was reported (among a total of 3781 patients treated with telmisartan).
Adverse experiences that have been reported with hydrochlorothiazide, without regard to causality, are listed as follows: Body as a whole:
pancreatitis, jaundice (intrahepatic cholestatic jaundice), sialadenitis, cramping, gastric irritation.
aplastic anemia, agranulocytosis, leukopenia, hemolytic anemia, thrombocytopenia.
purpura, photosensitivity, urticaria, necrotizing angiitis (vasculitis and cutaneous vasculitis), fever, respiratory distress including pneumonitis and pulmonary edema, anaphylactic reactions.
hyperglycemia, glycosuria, hyperuricemia.
renal failure, renal dysfunction, interstitial nephritis.
erythema multiforme including Stevens-Johnson syndrome, exfoliative dermatitis including toxic epidermal necrolysis.
transient blurred vision, xanthopsia.
Clinical Laboratory Findings:
In controlled trials, clinically relevant changes in standard laboratory test parameters were rarely associated with administration of PACSARTAN-TH tablets.